• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Murali Ramachandran claimed ownership of 132,857 shares (SEC Form 3)

    9/24/24 9:00:12 PM ET
    $KAPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KAPA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Murali Ramachandran

    (Last) (First) (Middle)
    C/O KAIROS PHARMA, LTD.
    2355 WESTWOOD BLVD., #139

    (Street)
    LOS ANGELES CA 90064

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/16/2024
    3. Issuer Name and Ticker or Trading Symbol
    Kairos Pharma, LTD. [ KAPA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP of Research and Development
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    COMMON STOCK 132,857 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Ramachandran Murali 09/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KAPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KAPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KAPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP of Research and Development Murali Ramachandran bought $318 worth of shares (200 units at $1.59), increasing direct ownership by 0.15% to 133,057 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      11/25/24 8:30:12 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Samuelson Doug bought $3,750 worth of shares (2,500 units at $1.50), increasing direct ownership by 4% to 60,796 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      11/25/24 6:03:39 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Yu John S bought $5,760 worth of shares (4,000 units at $1.44), increasing direct ownership by 0.07% to 5,341,837 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      11/21/24 9:53:44 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KAPA
    SEC Filings

    See more
    • SEC Form PRER14A filed by Kairos Pharma Ltd.

      PRER14A - Kairos Pharma, LTD. (0001962011) (Filer)

      5/6/25 12:20:58 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kairos Pharma Ltd. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Kairos Pharma, LTD. (0001962011) (Filer)

      4/28/25 5:28:41 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Kairos Pharma Ltd.

      424B3 - Kairos Pharma, LTD. (0001962011) (Filer)

      4/25/25 5:13:47 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KAPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Singhvi Rahul claimed ownership of 30,120 shares (SEC Form 3)

      3 - Kairos Pharma, LTD. (0001962011) (Issuer)

      4/30/25 4:10:05 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Bhowmick Neil was granted 14,000 shares, increasing direct ownership by 1% to 1,139,983 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      4/7/25 8:30:18 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP of Research and Development Murali Ramachandran was granted 14,000 shares, increasing direct ownership by 11% to 147,057 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      2/24/25 6:52:11 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KAPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

      Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," and will be presented on June 2. John Yu, M.D., Kairos CEO commented, "We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer tr

      4/28/25 8:00:00 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kairos Pharma Ltd. Provides Letter to Stockholders

      Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stockholders, As we reflect on the Company's progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds. We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarker

      4/24/25 8:00:00 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

      Kairos Pharma, Ltd. (NYSE:KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense ("DoD") is providing $876,000 to advance a strategy to identify patients that are starting to develop resistance at an early stage. The grant was awarded to identify biomarkers for the Company's clinical study to address the major challenge in achieving a lasting cure for lung cancer patients. The g

      4/17/25 8:00:00 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care